FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1876031798> ?p ?o ?g. }

• W1876031798 endingPage "1485" @default.
• W1876031798 startingPage "1476" @default.
• W1876031798 abstract "BackgroundShort-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure.ObjectiveWe sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school.MethodsA 3-arm, randomized, double-blind, double placebo-controlled, multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined.ResultsBefore the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate was significantly lower in the omalizumab versus placebo arms (11.3% vs 21.0%; odds ratio [OR], 0.48; 95% CI, 0.25-0.92), but there was no significant difference between omalizumab and ICS boost (8.4% vs 11.1%; OR, 0.73; 95% CI, 0.33-1.64). In a prespecified subgroup analysis, among participants with an exacerbation during the run-in phase, omalizumab was significantly more efficacious than both placebo (6.4% vs 36.3%; OR, 0.12; 95% CI, 0.02-0.64) and ICS boost (2.0% vs 27.8%; OR, 0.05; 95% CI, 0.002-0.98). Omalizumab improved IFN-α responses to rhinovirus, and within the omalizumab group, greater IFN-α increases were associated with fewer exacerbations (OR, 0.14; 95% CI, 0.01-0.88). Adverse events were rare and similar among arms.ConclusionsAdding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation. Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure. We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school. A 3-arm, randomized, double-blind, double placebo-controlled, multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined. Before the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate was significantly lower in the omalizumab versus placebo arms (11.3% vs 21.0%; odds ratio [OR], 0.48; 95% CI, 0.25-0.92), but there was no significant difference between omalizumab and ICS boost (8.4% vs 11.1%; OR, 0.73; 95% CI, 0.33-1.64). In a prespecified subgroup analysis, among participants with an exacerbation during the run-in phase, omalizumab was significantly more efficacious than both placebo (6.4% vs 36.3%; OR, 0.12; 95% CI, 0.02-0.64) and ICS boost (2.0% vs 27.8%; OR, 0.05; 95% CI, 0.002-0.98). Omalizumab improved IFN-α responses to rhinovirus, and within the omalizumab group, greater IFN-α increases were associated with fewer exacerbations (OR, 0.14; 95% CI, 0.01-0.88). Adverse events were rare and similar among arms. Adding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation." @default.
• W1876031798 created "2016-06-24" @default.
• W1876031798 creator A5001991232 @default.
• W1876031798 creator A5012934813 @default.
• W1876031798 creator A5013823897 @default.
• W1876031798 creator A5026189939 @default.
• W1876031798 creator A5028755534 @default.
• W1876031798 creator A5033765434 @default.
• W1876031798 creator A5033821656 @default.
• W1876031798 creator A5038055384 @default.
• W1876031798 creator A5044980958 @default.
• W1876031798 creator A5048755545 @default.
• W1876031798 creator A5053044434 @default.
• W1876031798 creator A5055308791 @default.
• W1876031798 creator A5055345150 @default.
• W1876031798 creator A5063976675 @default.
• W1876031798 creator A5064437485 @default.
• W1876031798 creator A5068383869 @default.
• W1876031798 creator A5072054959 @default.
• W1876031798 creator A5075813861 @default.
• W1876031798 creator A5084973045 @default.
• W1876031798 creator A5089464378 @default.
• W1876031798 date "2015-12-01" @default.
• W1876031798 modified "2023-10-16" @default.
• W1876031798 title "Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations" @default.
• W1876031798 cites W1958095205 @default.
• W1876031798 cites W1965301392 @default.
• W1876031798 cites W1970703972 @default.
• W1876031798 cites W1984012752 @default.
• W1876031798 cites W1988758075 @default.
• W1876031798 cites W1997414500 @default.
• W1876031798 cites W2015891257 @default.
• W1876031798 cites W2036104571 @default.
• W1876031798 cites W2037466531 @default.
• W1876031798 cites W2043387305 @default.
• W1876031798 cites W2048725737 @default.
• W1876031798 cites W2060952785 @default.
• W1876031798 cites W2061775758 @default.
• W1876031798 cites W2071295142 @default.
• W1876031798 cites W2084958270 @default.
• W1876031798 cites W2086768206 @default.
• W1876031798 cites W2095754126 @default.
• W1876031798 cites W2098931866 @default.
• W1876031798 cites W2098968578 @default.
• W1876031798 cites W2103090698 @default.
• W1876031798 cites W2112433605 @default.
• W1876031798 cites W2112649669 @default.
• W1876031798 cites W2115252063 @default.
• W1876031798 cites W2121954044 @default.
• W1876031798 cites W2124585444 @default.
• W1876031798 cites W2146852572 @default.
• W1876031798 cites W2148750103 @default.
• W1876031798 cites W2149411747 @default.
• W1876031798 cites W2154069165 @default.
• W1876031798 cites W4239218095 @default.
• W1876031798 cites W4241185252 @default.
• W1876031798 doi "https://doi.org/10.1016/j.jaci.2015.09.008" @default.
• W1876031798 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4679705" @default.
• W1876031798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26518090" @default.
• W1876031798 hasPublicationYear "2015" @default.
• W1876031798 type Work @default.
• W1876031798 sameAs 1876031798 @default.
• W1876031798 citedByCount "425" @default.
• W1876031798 countsByYear W18760317982015 @default.
• W1876031798 countsByYear W18760317982016 @default.
• W1876031798 countsByYear W18760317982017 @default.
• W1876031798 countsByYear W18760317982018 @default.
• W1876031798 countsByYear W18760317982019 @default.
• W1876031798 countsByYear W18760317982020 @default.
• W1876031798 countsByYear W18760317982021 @default.
• W1876031798 countsByYear W18760317982022 @default.
• W1876031798 countsByYear W18760317982023 @default.
• W1876031798 crossrefType "journal-article" @default.
• W1876031798 hasAuthorship W1876031798A5001991232 @default.
• W1876031798 hasAuthorship W1876031798A5012934813 @default.
• W1876031798 hasAuthorship W1876031798A5013823897 @default.
• W1876031798 hasAuthorship W1876031798A5026189939 @default.
• W1876031798 hasAuthorship W1876031798A5028755534 @default.
• W1876031798 hasAuthorship W1876031798A5033765434 @default.
• W1876031798 hasAuthorship W1876031798A5033821656 @default.
• W1876031798 hasAuthorship W1876031798A5038055384 @default.
• W1876031798 hasAuthorship W1876031798A5044980958 @default.
• W1876031798 hasAuthorship W1876031798A5048755545 @default.
• W1876031798 hasAuthorship W1876031798A5053044434 @default.
• W1876031798 hasAuthorship W1876031798A5055308791 @default.
• W1876031798 hasAuthorship W1876031798A5055345150 @default.
• W1876031798 hasAuthorship W1876031798A5063976675 @default.
• W1876031798 hasAuthorship W1876031798A5064437485 @default.
• W1876031798 hasAuthorship W1876031798A5068383869 @default.
• W1876031798 hasAuthorship W1876031798A5072054959 @default.
• W1876031798 hasAuthorship W1876031798A5075813861 @default.
• W1876031798 hasAuthorship W1876031798A5084973045 @default.
• W1876031798 hasAuthorship W1876031798A5089464378 @default.
• W1876031798 hasBestOaLocation W18760317981 @default.
• W1876031798 hasConcept C126322002 @default.
• W1876031798 hasConcept C141105273 @default.
• W1876031798 hasConcept C142724271 @default.
• W1876031798 hasConcept C156957248 @default.

• next